These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22329794)

  • 41. Seroprevalence of seasonal and pandemic influenza a in Kuala Lumpur, Malaysia in 2008-2010.
    Sam IC; Shaw R; Chan YF; Hooi PS; Hurt AC; Barr IG
    J Med Virol; 2013 Aug; 85(8):1420-5. PubMed ID: 23765779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic.
    Reed C; Katz JM; Hancock K; Balish A; Fry AM;
    PLoS One; 2012; 7(10):e48187. PubMed ID: 23118949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection.
    Fox A; Mai le Q; Thanh le T; Wolbers M; Le Khanh Hang N; Thai PQ; Thi Thu Yen N; Minh Hoa le N; Bryant JE; Duong TN; Thoang DD; Barr IG; Wertheim H; Farrar J; Hien NT; Horby P
    J Infect; 2015 Feb; 70(2):187-96. PubMed ID: 25224643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal seroepidemiologic study of the 2009 pandemic influenza A (H1N1) infection among health care workers in a children's hospital.
    Yen TY; Lu CY; Chang LY; Tsai YT; Huang LM
    BMC Infect Dis; 2012 Apr; 12():89. PubMed ID: 22498010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
    Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seroprevalence following the first wave of pandemic influenza A (H1N1) in Turkey, 2009.
    Gözalan A; Altaş AB; Sevencan F; Akın L; Korukluoğlu G; Kara S; Sevindi DF; Ertek M;
    Jpn J Infect Dis; 2012; 65(1):13-8. PubMed ID: 22274152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina.
    Labato MI; Contrini MM; Lazzarini D; Campos AM; Gauna ML; Claros R; López EL; Savy VL; Luna CM
    Int J Infect Dis; 2014 Feb; 19():20-5. PubMed ID: 24211378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan.
    Chan YJ; Lee CL; Hwang SJ; Fung CP; Wang FD; Yen DH; Tsai CH; Chen YM; Lee SD
    J Chin Med Assoc; 2010 Feb; 73(2):62-6. PubMed ID: 20171584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serological response in RT-PCR confirmed H1N1-2009 influenza a by hemagglutination inhibition and virus neutralization assays: an observational study.
    Chen MI; Barr IG; Koh GC; Lee VJ; Lee CP; Shaw R; Lin C; Yap J; Cook AR; Tan BH; Loh JP; Barkham T; Chow VT; Lin RT; Leo YS
    PLoS One; 2010 Aug; 5(8):e12474. PubMed ID: 20814575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.
    Uno S; Kimachi K; Matsuo F; Miyazaki K; Oohama A; Kei J; Nishimura T; Odoh K; Kino Y
    Microbiol Immunol; 2012 Dec; 56(12):810-6. PubMed ID: 23009167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantifying homologous and heterologous antibody titre rises after influenza virus infection.
    Freeman G; Perera RA; Ngan E; Fang VJ; Cauchemez S; Ip DK; Peiris JS; Cowling BJ
    Epidemiol Infect; 2016 Aug; 144(11):2306-16. PubMed ID: 27018720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H1N1 hemagglutinin-inhibition seroprevalence in Emergency Department Health Care workers after the first wave of the 2009 influenza pandemic.
    Kumar S; Fan J; Melzer-Lange M; Trost J; Havens PL; Willoughby RE; Chusid MJ; Henrickson KJ
    Pediatr Emerg Care; 2011 Sep; 27(9):804-7. PubMed ID: 21878831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in seroprevalence of antibodies to pandemic influenza H1N1 (2009) virus among patients seeking care in China.
    Xu C; Bai T; Wang M; Chen T; Wang L; Chen M; Zeng Y; Fan Ch; Yuan F; Shi J; Sun S; Li D; Wang S; Feng Z; Zhang Y; Yu H; Yang W; Wang Y; Shu Y
    Acta Virol; 2012; 56(4):329-35. PubMed ID: 23237089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.